STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
STERIS Dividend Announcement
• STERIS announced a quarterly dividend of $0.57 per ordinary share which will be made payable on 2024-12-19. Ex dividend date: 2024-11-19
• STERIS annual dividend for 2024 was $2.18
• STERIS annual dividend for 2023 was $1.98
• STERIS's trailing twelve-month (TTM) dividend yield is 1.22%
• STERIS's payout ratio for the trailing twelve months (TTM) is 48.40%
• STERIS's dividend growth over the last five years (2018-2023) was 8.78% year
• STERIS's dividend growth over the last ten years (2013-2023) was 9.49% year
STERIS Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-11-19 | $0.57 | quarterly | 2024-12-19 |
2024-09-05 | $0.57 | quarterly | 2024-09-20 |
2024-06-12 | $0.52 | quarterly | 2024-06-26 |
2024-02-22 | $0.52 | quarterly | 2024-03-22 |
2023-11-20 | $0.52 | quarterly | 2023-12-21 |
2023-09-05 | $0.52 | quarterly | 2023-09-22 |
2023-06-13 | $0.47 | quarterly | 2023-06-28 |
2023-02-23 | $0.47 | quarterly | 2023-03-23 |
2022-11-21 | $0.47 | quarterly | 2022-12-16 |
2022-09-06 | $0.47 | quarterly | 2022-09-23 |
2022-06-13 | $0.43 | quarterly | 2022-06-28 |
2022-02-24 | $0.43 | quarterly | 2022-03-24 |
2021-11-22 | $0.43 | quarterly | 2021-12-17 |
2021-09-02 | $0.43 | quarterly | 2021-09-24 |
2021-05-27 | $0.40 | quarterly | 2021-06-25 |
2021-02-23 | $0.40 | quarterly | 2021-03-25 |
2020-11-23 | $0.40 | quarterly | 2020-12-18 |
2020-08-26 | $0.40 | quarterly | 2020-09-24 |
2020-06-11 | $0.37 | quarterly | 2020-06-26 |
2020-02-24 | $0.37 | quarterly | 2020-03-26 |
2019-11-25 | $0.37 | quarterly | 2019-12-20 |
2019-09-09 | $0.37 | quarterly | 2019-09-26 |
2019-06-11 | $0.34 | quarterly | 2019-06-28 |
2019-02-26 | $0.34 | quarterly | 2019-03-21 |
2018-11-27 | $0.34 | quarterly | 2018-12-21 |
2018-08-28 | $0.34 | quarterly | 2018-09-27 |
2018-06-07 | $0.31 | quarterly | 2018-06-28 |
2018-02-27 | $0.31 | quarterly | 2018-03-28 |
2017-11-21 | $0.31 | quarterly | 2017-12-20 |
2017-08-25 | $0.31 | quarterly | 2017-09-28 |
2017-06-05 | $0.28 | quarterly | 2017-06-29 |
2017-02-24 | $0.28 | quarterly | 2017-03-28 |
2016-11-21 | $0.28 | quarterly | 2016-12-21 |
2016-08-26 | $0.28 | quarterly | 2016-09-27 |
2016-06-06 | $0.25 | quarterly | 2016-06-29 |
2016-02-26 | $0.25 | quarterly | 2016-03-29 |
2015-10-28 | $0.25 | quarterly | 2015-12-18 |
2015-08-21 | $0.25 | quarterly | 2015-09-22 |
2015-06-01 | $0.23 | quarterly | 2015-06-25 |
2015-02-23 | $0.23 | quarterly | 2015-03-25 |
2014-11-24 | $0.23 | quarterly | 2014-12-23 |
2014-08-22 | $0.23 | quarterly | 2014-09-23 |
2014-06-03 | $0.21 | quarterly | 2014-06-26 |
2014-02-24 | $0.21 | quarterly | 2014-03-26 |
2013-11-18 | $0.21 | quarterly | 2013-12-18 |
2013-08-26 | $0.21 | quarterly | 2013-09-25 |
2013-05-31 | $0.19 | quarterly | 2013-06-25 |
2013-02-25 | $0.19 | quarterly | 2013-03-27 |
STERIS Dividend per year
STERIS Dividend growth
STERIS Dividend Yield
STERIS current trailing twelve-month (TTM) dividend yield is 1.22%. Interested in purchasing STERIS stock? Use our calculator to estimate your expected dividend yield:
STERIS Financial Ratios
STERIS Dividend FAQ
Other factors to consider when evaluating STERIS as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy STERIS stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: STERIS's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, STERIS publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, STERIS distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from STERIS are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: STERIS sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, STERIS distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: STERIS declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of STERIS's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review STERIS's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.